HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $40 to $42.
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $40 to $42.